Effect of Prophylactic Palivizumab on Admission Due to Respiratory Syncytial Virus Infection in Former Very Low Birth Weight Infants with Bronchopulmonary Dysplasia.
10.3346/jkms.2015.30.7.924
- Author:
Young Mi HAN
1
;
Hyun Joo SEO
;
Seo Heui CHOI
;
Yu Jin JUNG
;
So Yoon AHN
;
Hye Soo YOO
;
Se In SUNG
;
Jae Won SHIM
;
Yeon Kyung LEE
;
Sun Young KO
;
Son Moon SHIN
;
Jong Hee HWANG
;
Jang Hoon LEE
;
Byung Min CHOI
;
Eun Sun KIM
;
Ji Hyun JEON
;
Sung Shin KIM
;
Yun Sil CHANG
;
Won Soon PARK
Author Information
1. Department of Pediatrics, Pusan National University School of Medicine, Children's Hospital, Yangsan, Korea.
- Publication Type:Original Article ; Multicenter Study ; Observational Study ; Research Support, Non-U.S. Gov't
- Keywords:
Respiratory Syncytial Viruses;
Palivizumab;
Hospitalization;
Bronchopulmonary Dysplasia;
Preterm;
Infant
- MeSH:
Antibiotic Prophylaxis/*methods;
Antiviral Agents/*therapeutic use;
Birth Weight;
Bronchopulmonary Dysplasia/*complications;
Female;
Gestational Age;
Hospitalization/statistics & numerical data;
Humans;
Infant;
Infant, Newborn;
Infant, Premature;
*Infant, Very Low Birth Weight;
Length of Stay;
Male;
Palivizumab/*therapeutic use;
Prospective Studies;
Respiratory Syncytial Virus Infections/drug therapy/*epidemiology/prevention & control;
Respiratory Syncytial Viruses/drug effects;
Risk;
Risk Factors
- From:Journal of Korean Medical Science
2015;30(7):924-931
- CountryRepublic of Korea
- Language:English
-
Abstract:
The aim of this study was to observe the effects of prophylactic palivizumab on hospitalization secondary to respiratory syncytial virus (RSV) infection (RSVhospitalization) in former very low birth weight infants (VLBWI) with bronchopulmonary dysplasia (BPD). This study also sought to identify the risk factors of RSVhospitalizationin this particular infant population. A prospective observational study was conducted between September 2007 and April 2008 in seven Korean hospitals. Children with a history of very low birth weight, a diagnosis of BPD and who were <2 yr old at the onset of the RSV season were included in this study. Palivizumab injections were administered monthly for a maximum of five months during the RSV season. RSVhospitalization rates were reviewed, and RSVhospitalization rates between subgroups were categorized by gestational age, birth weight, and duration of ventilator care. A total of 90 subjects completed the follow-up interviews. The mean gestational age at birth was 26.1+/-1.7 weeks, and the mean birth weight was 889.4+/-222.2 g. The incidence of RSVhospitalization in the study population was 8.9% (8/90), and the mean hospital stay was 11.0+/-5.5 days, including one death. There were no statistically significant differences in the patients' demographic characteristics or risk factors for RSV hospitalization. When subgroup analyses were conducted, there were still no statistically significant differences. The administration of palivizumab prophylaxis during the entire RSV season is important in VLBWI with BPD, regardless of their gestational age and birth weight, or previous ventilator dependency.
